Gilead Partners with Tubulis for Solid Tumor ADC Development in $465M Deal

Gilead Sciences has embarked on a promising partnership with Tubulis, a German biotechnology company, to develop antibody-drug conjugates (ADCs) aimed at treating solid tumors. This alliance involves an initial $20 million investment with the possibility of an additional $30 million if Gilead opts to continue with the exclusive licensing, leading to a potential total deal value of $465 million including milestone payments and royalties[1][2]. The partnership will focus on utilizing Tubulis' cutting-edge Tubutecan and P5 conjugation platforms, which have demonstrated promising results in preclinical models of various cancers including ovarian, lung, and triple-negative breast cancers[1][2]. Through this collaboration, Gilead aims to strengthen its oncology portfolio and recover from previous ADC development setbacks, including challenges faced with its Trodelvy program[2].